Right. Well, absolutely. Right. I think actually we presented this during the session where we had a brilliant discussion answering your question, basically. Right. We have a wave of different compounds. You know, for the most part, PSMA has been the most common target being explored. Small molecules, antibody. We had different, you know, different molecules, beta emitters, alpha emitters, lutetium, actinium are the ones we’ve been talking the most, but there are others like terbium, like, you know, lead...
Right. Well, absolutely. Right. I think actually we presented this during the session where we had a brilliant discussion answering your question, basically. Right. We have a wave of different compounds. You know, for the most part, PSMA has been the most common target being explored. Small molecules, antibody. We had different, you know, different molecules, beta emitters, alpha emitters, lutetium, actinium are the ones we’ve been talking the most, but there are others like terbium, like, you know, lead. And so, you know, and so there is an overwhelming number of studies investigating these different therapies. They’re also being investigated in particular different, very different settings, late-line, pre-chemotherapy, ARPI naive, even in a non-metastatic space, combined with radiation therapy prior to surgery. So, you know, it’s really hard to keep up. There’s a lot of good science and research being conducted around the globe on this. And so it’s extremely difficult to answer the question with specifics other than saying that, you know, I think the landscape of prostate cancer or the treatment landscape of prostate cancer will very, very likely include therapies beyond lutetium PSMA, which is available today for patients who present with metastatic disease and progress on prior ARPI. And in some places of the globe also must have progressed on taxane-based chemo. So I do think we’re going to hear a lot more. I don’t think it’s going to go away. And I do think we have to figure it out better, you know, as we understand the safety, how does that impact the management overall, but also we need to figure out how we actually, you know, sequence them, right? Because I think we’re going to be using more than one in the near future.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
